Therapy Trends Updates - Page 1

Learn More Future Innovation in Oncology: Update Bulletin # 2 [January 2019]

This edition presents key opinion leader (KOL) views on data presentations given at American Society of Hematology’s Annual Meeting 2018 (ASH 2018), held in December 2018. Topics covered include: Regeneron’s...

Compare
Learn More Prostate Cancer: Update Bulletin #1 [January 2019]

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Bayer and Orion announcing that their androgen receptor antagonist darolutamide (ODM-201)...

Compare
Learn More Psoriasis: Update Bulletin #2 [January 2019]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the psoriasis market. Topics covered include opinions...

Compare
Learn More CAR-T therapies in Haematological Malignancy: Update Bulletin #3 [January 2019]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US on a variety of recent events in the CAR-T therapy space. KOLs provide their candid insights on...

Compare
Learn More Chronic Pulmonary Obstructive Disorder (COPD): Update Bulletin #3 [January 2019]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the COPD market. Within this update, KOLs provided their views on the...

Compare
Learn More Ovarian Cancer: Update Bulletin #3 [January 2019]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the ovarian cancer market. KOLs provide...

Compare
Learn More Renal Cell Carcinoma: Update Bulletin #2 [December 2018]

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the renal cell carcinoma (RCC) market, including: Positive...

Compare
Learn More Rheumatoid Arthritis: Update Bulletin #3 [December 2018]

This edition presents key opinion leader (KOL) views on recent developments in the rheumatoid arthritis (RA) market. Topics covered include: Gilead Sciences and Galapagos announcing that the investigational JAK1...

Compare
Learn More Non-Hodgkin's Lymphoma: Update Bulletin #1 [December 2018]

This edition presents key opinion leader (KOL) views on recent developments in the non-Hodgkin’s lymphoma (NHL) market. Topics covered include: Unum Therapeutics announcing that it expects to complete enrolment in...

Compare
Learn More Multiple Myeloma: Update Bulletin #2 [December 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the multiple myeloma (MM) market. Topics covered...

Compare
Learn More Head and Neck Squamous Cell Carcinoma (HNSCC): Update Bulletin #3 [December 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the head and neck squamous cell carcinoma (HNSCC)...

Compare
Learn More Gastric Cancer: Update Bulletin #2 [December 2018]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of gastric cancer (GC). Topics covered include KOL views on; Leap Therapeutics’ presentation of data from the P102 study...

Compare
Learn More Diabetes (Early Stage Outlook) : Update Bulletin #1 [December 2018]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the diabetes mellitus (DM) market. Within this update, KOLs provided their...

Compare
Learn More Colorectal Cancer: Update Bulletin #1 [December 2018]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the colorectal cancer (CRC) market. Within this update, KOLs provided...

Compare
Learn More Atopic Dermatitis: Update Bulletin #1 [December 2018]

This edition presents key opinion leader (KOL) views on recent developments in the atopic dermatitis (AD) market. Topics covered include: Galderma announcing positive results from a Phase IIb dose-ranging study of...

Compare
Learn More Non-Small Cell Lung Cancer (NSCLC): Update Bulletin #1 [November 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US on a variety of recent events in the non-small cell lung cancer (NSCLC) market. KOLs provide...

Compare

Browse by